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Infrarenal aortic infection continues to be one of
the most challenging problems in modern vascular
surgery. Successful treatment necessitates the com-
plete excision of the infrarenal aortic infection with
the maintenance of adequate lower extremity arterial
inflow. Patient survival, freedom from recurrent infec-
tion, patency of the revascularization, and avoidance
of major amputation are important outcome goals
used to measure the success of surgical treatment.
The conventional surgical treatment of infrarenal
aortic infection (primary and prosthetic graft)
includes the excision and drainage of infection with
the oversewing of the infrarenal aorta combined
with axillofemoral bypass grafting. Historically,
problems with this approach have included aortic
stump blow-out and axillofemoral bypass graft fail-
ure, which includes both graft thrombosis and infec-
tion. A summary of the results published through
1983 included an overall operative mortality rate for
aortic prosthetic graft infection that ranged from
20% to 38%, with surgical management consisting of
aortic graft excision and extra-anatomic bypass graft-
ing.1,2 The incidence rate of subsequent infection of
the axillofemoral bypass graft was reported to be as
high as 40%.3 These disappointing results have
understandably kindled interest in alternative
approaches to the management of infrarenal aortic
infection, including direct in situ aortic reconstruc-
tion with the use of autogenous vein grafts and aor-
tic allografts.4,5 During the past decade, however,
the results have improved with the conventional sur-
gical management of infrarenal aortic infection.6-9
This undoubtably reflects a number of factors,
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including specialized training in vascular surgery,
advances in intensive care and anesthetic techniques,
more effective antibiotics, and refinements in both
surgical technique and graft material used for
axillofemoral bypass grafting. In comparison with
numerous enthusiastic reports touting alternative
approaches, the improved results with conventional
surgical management seem to have gone relatively
unheralded. The purpose of this report is to docu-
ment and emphasize the improved results with the
management of infrarenal aortic infection (both pri-
mary and prosthetic graft) by conventional surgical
means, defined as axillofemoral bypass grafting, fol-
lowed by the complete excision and drainage of the
infrarenal infection.
PATIENTS AND METHODS
From January 1983 through June 1998, patients
with infrarenal aortic infection at our combined
(Veterans Affairs Medical Center/University Hospital)
vascular service were prospectively entered into a com-
puterized database. The diagnosis of infrarenal aortic
infection was made on the basis of clinical presentation
(fever, leukocytosis, blood cultures, draining wounds,
gastrointestinal hemorrhage) and computed tomo-
graphic scanning of the infrarenal aorta. Computed
tomographic scan evidence of perigraft or periaortic
fluid or gas was considered to be consistent with
infrarenal aortic infection. The patients with infrarenal
aortic infection underwent management with axillo-
femoral bypass grafting and complete excision of the
infected aorta or graft. The patients initially underwent
treatment with intravenous antibiotics. Preoperative
arteriography of the aorta and lower extremities was
routinely performed when possible.
Surgical technique. Preliminary axillobifemoral
bypass grafting was performed with a two-team
approach and an externally supported 8-mm polyte-
trafluoroethylene graft. Before axillofemoral bypass
grafting, any open wounds or draining sinus tracts
were isolated with adhesive sterile dressings. Through
an infraclavicular incision, the axillary anastomosis was
made end to side to the first portion of the axillary
artery medial to the pectoralis minor muscle. The
femoral anastomoses were made through incisions
remote to any areas involved in the infection. The
common femoral artery was preferred for the distal
anastomosis if it was uninvolved with infection. When
necessary, however, distal anastomoses were con-
structed to the profunda femoral arteries or to the
superficial femoral arteries beyond the inguinal region
through lateral incisions. The polytetrafluoroethylene
graft was tunneled subcutaneously from the femoral
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incision to the infraclavicular incision. Currently, the
graft is routed adjacent and parallel to the axillary
artery for a distance of 8 to 10 cm before passing in a
gentle curve inferiorly to minimize axillary graft dis-
ruption.10
After the completion of the anastomoses, all the
incisions were closed and excluded with adhesive
dressings before approaching the infrarenal aortic
infection through a midline incision. The infected
graft or aorta was excised in entirety, and the
wounds were cultured and debrided. In patients
with aortoenteric fistulae, the bowel defect was
repaired with lateral closure. The aortic stump was
closed with at least two layers of monofilament
suture, and the iliofemoral vessels were ligated. The
patients with gross purulence underwent dependent
drainage of the retroperitoneum with soft rubber
drains exiting directly posterior between the left
psoas muscle and left kidney.11
Postoperative management and follow-up exam-
ination. Intravenous antibiotics were administered for
2 weeks, and culture-determined oral antibiotics were
continued for up to 6 months. After discharge and
wound healing, the patients were seen every 3 months
for the first year and every 6 months thereafter. The
patients routinely were prescribed daily aspirin dosage.
Axillofemoral graft patency was assessed with clinical
and noninvasive vascular laboratory examination. Long-
term primary patency, graft failure, limb salvage, and
survival rates were determined with standard life-table
analysis. Primary patency was terminated at the time of
initial axillofemoral graft revision or replacement.
Axillofemoral graft thrombosis was managed by means
of placement of a new axillofemoral graft rather than
attempt of thrombectomy and old graft revision.
Because patients with thrombosed grafts did not under-
go treatment with thrombectomy, there was no sec-
ondary graft patency. A composite extra-anatomic graft
patency rate was calculated, which included patients
with redo axillofemoral grafts. Graft failure was calculat-
ed with the inclusion of patients with either graft infec-
tion or occlusion. Statistical differences among groups
were tested with log-rank test and c 2 test.
RESULTS
During the 15-year study period, 60 patients (51
men, nine women; mean age 68 years, range 32 to
84 years) underwent treatment for infrarenal aortic
infection (50 aortic graft infections, including 16
graft-enteric fistulae/erosions, and 10 primary aor-
toiliac infections). Of the 16 patients with bowel
involvement, six had a true fistula and 10 had a graft-
enteric erosion. The mean interval from time of aor-
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tic graft insertion to diagnosis of graft infection was
97 months (range, 2 to 288 months). Some patients
had undergone additional, more recent operations
on their aortic grafts, including thrombectomy/revi-
sion, repair of anastomotic aneurysm, or femoral-dis-
tal bypass grafting. Of the aortic grafts, 29 (58%)
were originally placed for occlusive disease and 21
(42%) were placed for aneurysmal disease.
Fifty-eight patients (97%) underwent extra-
anatomic revascularization (47 axillobifemoral, four
bilateral axillofemoral, four unilateral axillofemoral,
and three femoral-femoral grafts). The three femoral-
femoral grafts were used to perform revascularization
on two patients with infected iliac artery aneurysms
and on one patient with aortofemoral graft limb infec-
tion. The mean length of operation for axillofemoral
grafting and aortic procedure was 6.0 hours (range,
2.9 to 10.5 hours). One patient died before revascu-
larization, and one patient with previous bilateral
lower extremity amputations did not undergo revas-
cularization.
All the patients with graft-enteric fistula/erosion
showed multiple enteric organisms from the graft on
culture. The bacteriology data from patients with
aortic graft infection without bowel involvement are
shown in Table I. The culture results in patients with
primary aortic infection included Salmonella in four
cases, Streptococcus in three cases, Bacteroides in one
case, and Shigella in one case. The culture data were
not available to review in the remaining case.
The mean follow-up period was 41 months. No
patient was lost to follow-up examination. The peri-
operative mortality rate was 13% (12% for graft infec-
tion, 20% for primary infection). The perioperative
mortality rate was 19% (3 of 16) for patients with
aortic graft-enteric fistula/erosion and 9% (3 of 34)
for patients with aortic graft infection without bowel
involvement. The perioperative mortality rate was
17% (1 of 6) for patients with graft-enteric fistula and
20% (2 of 10) for patients with graft-enteric erosion.
Perioperative death was caused by sepsis (three
patients), myocardial infarction (two patients), renal
failure (one patient), hemorrhagic shock as a result
of aortic graft-enteric fistula (one patient), and aspi-
Fig 1. Patient survival rates with life-table analysis.
Table I. Aortic prosthetic graft culture results (n =
32)*
Organism No. of cases† Percentage of cases
Staphylococcus aureus 14 44
Staphylococcus epidermidis 14 44
Bacteroides 3 9
Escherichia coli 2 6
Streptococcus 2 6
Klebsiella 1 3
Pseudomonas 1 3
Enterococcus 1 3
Clostridium 1 3
Serratia 1 3
Candida 1 3
Corynebacterium 1 3
Propionibacterium 1 3
No growth 2 6
*Cultures not obtainable in two cases.
†Multiple organisms reported in 10 cases.
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 1 Yeager et al 79
ration (one patient). A single patient had aortic
stump disruption at 4 months, which caused death.
The overall 2-year and 5-year survival rates were 67%
and 47%, respectively (Fig 1). The limb salvage rates
at 2 and 5 years were 93% and 82%, respectively (Fig
2). The 5-year primary axillofemoral graft patency
rate was 73%, and the composite extra-anatomic
graft patency rate was 92% (Fig 3). Major lower
extremity amputation was necessitated overall in six
patients (10%). Four patients required early amputa-
tion, two as a direct result of axillofemoral graft fail-
ure and two with patent axillofemoral grafts but
occlusion of femoral-tibial bypass grafts that were
necessary to treat severe lower extremity ischemia
unrelated to the infection. Two additional patients
with patent axillofemoral grafts required amputation
during the late follow-up period (>4 years after
surgery) at the time of femoral-tibial bypass graft
Fig 2. Overall limb salvage rates with life-table analysis
Fig 3. Primary axillofemoral graft patency and composite extra-anatomic graft patency rates
and overall freedom from axillofemoral graft failure with life-table analysis.
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occlusion. No patient had lower extremity compart-
ment syndrome after revascularization.
Infection of the extra-anatomic prosthetic graft
occurred in six patients (10%). Axillofemoral graft
infection was managed with graft excision and place-
ment of a new axillofemoral graft through a clean
operative field. During the follow-up period, one of
these patients had reinfection of the new axillofemoral
graft.
Overall, reoperation for axillofemoral graft revi-
sion, excision, or replacement was necessary in 14
patients (24%; six for infection, seven for occlusion,
and one for axillary disruption). There were two reop-
erative perioperative deaths (one stroke, one myocar-
dial infarction) after axillofemoral graft revision. These
two deaths occurred at 6 months and at 58 months
after the initial surgical treatment of the infrarenal aor-
tic infection. The overall freedom from graft failure
rate at 5 years was 68% (Fig 3). Axillofemoral graft fail-
ure occurred significantly more frequently among
patients who had an infected aortofemoral bypass graft
originally placed for occlusive disease (10 of 28; 36%)
as compared with all other patients with axillofemoral
grafts (4 of 30; 13%; P < .05; Fig 4).
DISCUSSION
The keen interest in alternative methods for the
management of infrarenal aortic infection is under-
standable given the sobering results historically
reported with conventional management. The alter-
native methods being investigated, however, also
have drawbacks and complications that necessitate
further analysis. Clagett et al4 reported their experi-
ence with 41 patients (27 with infected aortic pros-
thetic grafts) who underwent complete or partial aor-
toiliac/femoral reconstruction with superficial
femoral-popliteal veins. The early mortality rate was
7.9%, with a 5% amputation rate. The 5-year primary
patency and limb salvage rates were 85% and 86%,
respectively. It is noteworthy, however, that the mean
operative time for these complex aortic procedures
was 7.9 hours, which appears to be significantly
longer than our mean operative time of 6.0 hours. In
addition, in a few patients, there was evidence of sig-
nificant lower extremity morbidity, including com-
partment syndrome (12.5%) and lower extremity
paralysis/paresis (7.3%), presumably as the result of
the prolonged lower extremity ischemic time. In our
series, by comparison, there was no incidence of
lower extremity compartment syndrome or paralysis.
We minimized lower extremity ischemic time with
initial axillofemoral bypass grafting followed by
infrarenal aortic or graft excision.
Kieffer et al5 have recommended in situ aortic
allograft replacement as an alternative treatment for
infected infrarenal aortic prosthetic grafts. They
Fig 4. Freedom from axillofemoral graft failure with life-table analysis among patients who
had an infected aortofemoral bypass graft originally placed for occlusive disease compared with
all other patients with axillofemoral grafts.
reported 43 patients with reasonably good initial
results, including a perioperative mortality rate of
12% and no early amputations. There was, however,
one early death caused by the rupture of the native
aorta as a result of persistent infection, and three
patients required an early repeat operation for allo-
graft-related complications (one case each of occlu-
sion, septic rupture, and graft-enteric fistula). In
addition, there was one late death caused by persis-
tent or recurrent infection. Of additional concern is
the fact that 25% of the patients available for follow-
up examination (mean follow-up period, 13.8
months) had allograft-related complications, with
anastomotic stenoses being a common problem.
Three patients required early surgical revision of
their allografts, and microscopic examination results
of resected allograft specimens showed histopatho-
logic changes consistent with chronic rejection.
With additional follow-up examination, the overall
incidence of degenerative changes in these allografts
may prove to be unacceptable.
Other authors have recommended in situ pros-
thetic graft replacement for infrarenal aortic infec-
tion.12-14 Walker et al12 treated 23 patients with aor-
tic graft-enteric fistula with graft excision and place-
ment of a new prosthetic graft in the same location.
Seven patients (30%) had either perioperative death
or early post-discharge death as the result of persis-
tent sepsis or aortic anastomotic disruption. In spite
of these disappointing early results, there were some
long-term survivors in this series. A more recent
report from the same institution emphasized, how-
ever, that in situ prosthetic replacement grafting
should not be performed in patients with infrarenal
aortic perigraft purulence but may be considered in
patients with low-grade aortic graft infection and
negative blood and perigraft cultures.13 Obviously,
however, it is problematic to attempt to determine
before aortic graft excision precisely which patients
have low-grade infection.
Recently, other authors have reported results
that suggest an improvement in the treatment of
infrarenal aortic infection with conventional surgical
methods. Sharp et al9 have reported 22 patients with
aortic graft infection who underwent treatment with
extra-anatomic bypass grafting and graft excision.
The 30-day operative mortality rate was 4.3%, and
there were no instances of aortic stump blowout and
no amputations. Primary and secondary patency
rates for axillofemoral grafts were 80% and 87%,
respectively, at 3 years, and less than 5% of the
axillofemoral grafts had a secondary infection devel-
op. In addition, Kuestner et al15 have reported
improved results with the conventional surgical
management of the challenging problem of aortic
graft-enteric fistula. These clinical investigators com-
pared their modern-day surgical results with their
experience before 1980. Their modern results
included a 19% perioperative mortality rate and a 6%
early amputation rate with extra-anatomic bypass
grafting and aortic graft excision. This represented
an absolute reduction of 21% in mortality rate and
27% in limb-loss rate as compared with their experi-
ence before 1980. Our 19% perioperative mortality
rate in patients with graft-enteric fistula is equivalent
to their improved results.
The reduction in aortic stump blow-out and the
improved patency rate of axillofemoral bypass graft-
ing have both contributed to the improved modern
results with the conventional management of
infrarenal aortic infection. The introduction of the
externally supported prostheses and other technical
modifications of the axillofemoral bypass grafting
operation have undoubtedly had a positive influence
on outcomes.16,17 Nonetheless, the treatment of
infrarenal aortic infection is fraught with difficulties
no matter what method of management is selected.
Although our relatively large series shows improved
outcomes as compared with historical results, it is
noteworthy that 24% of our patients required
axillofemoral graft revision, excision, or replacement.
In our experience, axillofemoral graft failure appears
to occur significantly more often among those
patients with occlusive disease and aortofemoral graft
infection. However, only two patients required
amputation as a direct result of axillofemoral graft
failure. In addition, there were two perioperative
deaths after axillofemoral graft revision, although one
of these deaths occurred almost 5 years after the ini-
tial surgical treatment of the infrarenal aortic infec-
tion. Our results indicate that older patients at high-
risk will tolerate the revision of an extra-anatomic
bypass graft with relatively low morbidity and mor-
tality, which may not be the case with revision of in-
line aortic reconstructions.
On the basis of these data and the problems asso-
ciated with alternative treatments, we remain con-
vinced that conventional surgical management,
including initial axillofemoral bypass grafting and
complete excision, is the superior method of treat-
ment for infrarenal aortic infection.
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Dr Ronald J. Stoney (San Francisco, Calif).
Concerned that a trend to replace the conventional treat-
ment of aortic graft infection (extra-anatomic bypass and
graft excision) with in situ autogenous vein or aortic allo-
graft, the authors reviewed their modern (past 15 years)
experience with conventional therapy for 50 aortic grafts
and 10 primary aortic infections. Their results led them to
conclude that conventional treatment is equal or superior
to in situ strategies, and they therefore advocate conven-
tional treatment as the goal standard with which newer
strategies should be compared.
To agree or disagree with their thesis, I reviewed the
results with conventional therapy before and after 1985
and compared mortality and amputation rates with the
newer in situ strategies and the current conventional expe-
rience you heard.
Before 1986, mortality and amputation rates for con-
ventional therapy approached 50%, but results in this suc-
ceeding decade fell by half to under 25%. For example, at
the University of California, San Francisco, with aortoen-
teric fistulae, Reilly reported a 19% mortality and a 6%
amputation rate in 1995 (down from 21% and 28%, respec-
tively, from their earlier experience reported in 1986).
Clagett used autogenous femoral vein for in situ
replacement and reported a 7.9% mortality and a 5% ampu-
tation rate. These were improved results, but ischemic limb
complications were 12.5% (compartment syndrome) and
7% (neurologic) morbidity. Keiffer used aortic allograft for
in situ replacement and reported a 12% mortality and no
amputations. These were encouraging results, but later
complications of the allograft included one early death
from infection and three replacements of the allograft: one
occlusion, one infection, and one aortoenteric fistula. Late
anastomotic stricture was common (possibly because of
chronic rejection?).
Dr Yeager’s present report included 55 patients (47
graft infections and eight primary aortic infections) who
completed the entire conventional therapy. There were
seven deaths for a 12.5% mortality and four perioperative
amputations for a 7% amputation rate, comparable with
the reported in situ experience.
Their data permitted assessing two other parameters:
First, aortic stump dehiscence occurred in one of 55
patients (less than a 2% incidence).
Second, reoperation, necessary to maintain axillofemoral
graft patency, occurred in 14 of 48 survivors (a 29% inci-
dence). Two of these patients died (a 14% reoperative mor-
tality).
Dr Yeager’s results support the thesis that convention-
al therapy is comparable with newer in situ strategies:
namely, it preserves limb viability and function and it
removes the infective source safely. However, permanence
of the repair remains a challenge. We have addressed this
in selected patients with recurrent axillofemoral graft fail-
ure by reinsertion of an in situ prosthetic graft once the
original infection has resolved (6 or more months after
DISCUSSION
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conventional therapy). Conventional therapy in these
patients was a temporary bridge until a permanent solu-
tion, like the original operation, could be reestablished
(aortofemoral graft).
I have several questions for the authors.
1. Have they also reinserted aortofemoral grafts once
the infection is controlled to manage recurrent
axillofemoral graft failure? If so, what were the
results?
2. What are their recommendations for achieving a
secure aortic closure?
3. What are their indications for bilateral axillofemoral
versus unilateral axillofemoral-femoral grafts?
4. What was the mean length of stay for their con-
ventionally treated group? How did their costs
compare with the costs for patients undergoing in
situ grafting?
I enjoyed the presentation and the chance to review
the manuscript in a timely manner, and I thank the pro-
gram committee for the privilege of discussing the paper.
Thank you.
Dr Richard A. Yeager. Thank you, Dr Stoney, for your
discussion and questions. Two of our patients with recur-
rent axillofemoral graft failure have undergone reinsertion
of aortofemoral grafts at least 1 year after their original
treatment for infrarenal aortic infection. Currently, both
patients are well with no recurrent problems.
As far as how to achieve a secure aortic closure, I would
recommend that young surgeons read what has been writ-
ten on this topic by the group from San Francisco.
Complete excision of the infrarenal aortic infection with
adequate debridement of the aortic wall is of utmost
importance. As Dr Ehrenfield points out, on rare occasions
renal artery bypass grafting or relocation may be necessary
to permit adequate proximal aortic debridement. When
possible, circumferential dissection of the entire infrarenal
aorta facilitates a secure closure without tension. Optimally,
aortic stump closure is performed in two layers with a large
monofilament suture.
We performed bilateral axillofemoral bypass grafting
procedures in four patients with extensive infection in
both groins. There was concern with these patients that a
cross-femoral graft would not safely avoid the area of
infection.
The mean length of hospital stay was 33 days at the
University Hospital and slightly longer at the Veteran’s
Affairs Medical Center. I have no data on cost, but I have
no doubt that costs are considerable. I suppose it is a sign
of improved management of infrarenal aortic infection if
we are spending time discussing length of stay and costs
rather than perioperative death and amputation.
Thank you again, Dr Stoney, for your comments. We
are all indebted to you and your colleagues in San
Francisco who have done so much to advance our knowl-
edge and to influence our management of these challeng-
ing cases with infrarenal aortic infection.
